Can Group B Streptococcus (GBS) urinary tract infections (UTIs) be treated with Macrobid (nitrofurantoin)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 8, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Group B Streptococcus UTIs with Nitrofurantoin (Macrobid)

Yes, nitrofurantoin (Macrobid) is effective for treating Group B Streptococcus (GBS) urinary tract infections and is an appropriate treatment choice. 1

Evidence for Nitrofurantoin's Effectiveness Against GBS

Nitrofurantoin demonstrates excellent activity against GBS in urinary tract infections:

  • Clinical studies have shown that all GBS isolates tested were sensitive to nitrofurantoin, with only 2% showing intermediate sensitivity 1
  • Nitrofurantoin is specifically recommended for treatment of GBS bacteriuria during pregnancy 2
  • It has been in clinical use for over 35 years with a continuing safety record and lack of associated R-factor resistance compared to newer antimicrobials 3

Treatment Approach for GBS UTIs

For Non-Pregnant Patients:

  • Standard dosing of nitrofurantoin 100mg four times daily for 3-7 days is effective for uncomplicated UTIs 4
  • Nitrofurantoin demonstrates both symptomatic improvement and bacteriological cure for UTIs 4

For Pregnant Patients:

  • GBS bacteriuria in pregnancy requires special attention as it indicates heavy genital tract colonization 2
  • Women with GBS bacteriuria during pregnancy should:
    1. Receive appropriate treatment at time of diagnosis (nitrofurantoin is appropriate) 2
    2. Additionally receive intrapartum antibiotic prophylaxis during labor to prevent neonatal GBS disease 2
    3. Not require additional GBS screening at 35-37 weeks 2

Important Clinical Considerations

Benefits of Nitrofurantoin for GBS UTIs:

  • Reaches high bactericidal concentrations in the urinary tract 5
  • Induces minimal resistance in the vaginal bacterial flora 5
  • Particularly valuable for recurrent UTIs 5

Potential Limitations and Precautions:

  • Rare but serious adverse effects can occur, including systemic inflammatory response syndrome 6
  • Should be used with caution in patients with renal impairment
  • Not appropriate for pyelonephritis or systemic infections due to limited tissue penetration

Alternative Options if Nitrofurantoin Cannot Be Used

If a patient has contraindications to nitrofurantoin, antibiotic sensitivity testing should guide alternative choices. For GBS UTIs, other effective options may include:

  • Ampicillin (though 17% of isolates may show intermediate sensitivity) 1
  • Penicillin (though 15% of isolates may show decreased sensitivity) 1
  • Vancomycin (for penicillin-allergic patients) 1

In conclusion, nitrofurantoin is an excellent choice for treating GBS UTIs due to its high efficacy against GBS, good safety profile, and minimal impact on developing resistance. For pregnant women with GBS bacteriuria, appropriate treatment with nitrofurantoin at diagnosis plus intrapartum prophylaxis during labor is the recommended approach.

References

Research

Antibiotic resistance patterns of group B streptococcal clinical isolates.

Infectious diseases in obstetrics and gynecology, 2004

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Nitrofurantoin: an update.

Obstetrical & gynecological survey, 1989

Research

Randomised controlled trial of nitrofurantoin versus placebo in the treatment of uncomplicated urinary tract infection in adult women.

The British journal of general practice : the journal of the Royal College of General Practitioners, 2002

Research

Effective prophylaxis for recurrent urinary tract infections during pregnancy.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1992

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.